These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 25374314)
21. Compulsory licensing to regulated licensing: effects on the conflict between innovation and access in the pharmaceutical industry. Gillat A Food Drug Law J; 2003; 58(4):711-40. PubMed ID: 15027457 [No Abstract] [Full Text] [Related]
22. Patent reform in the US: what's at stake for pharmaceutical innovation? Yancey A; Stewart CN Expert Opin Ther Pat; 2010 May; 20(5):603-8. PubMed ID: 20402544 [TBL] [Abstract][Full Text] [Related]
23. Enforcing pharmaceutical and biotech patent rights in China. Zhang YP; Deng MM Nat Biotechnol; 2008 Nov; 26(11):1235-40. PubMed ID: 18997760 [No Abstract] [Full Text] [Related]
24. Pharmaceuticals and medical devices: business practices. Issue brief. Steiner DJ Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448 [No Abstract] [Full Text] [Related]
25. [Dosing regimens in second medical use patents]. Suganuma CA Cad Saude Publica; 2017 Sep; 33(9):e00096716. PubMed ID: 28977273 [TBL] [Abstract][Full Text] [Related]
26. Navigating the Hatch-Waxman Act's safe harbor. Jones PB Food Drug Law J; 2002; 57(3):475-89. PubMed ID: 12710407 [No Abstract] [Full Text] [Related]
27. Merck v. Integra: Supreme Court permits use of patented compounds to obtain Food and Drug Administration approvals. Manthei JR; Hathaway CR; Grant MA; Chung DD Food Drug Law J; 2006; 61(2):273-7. PubMed ID: 16903032 [No Abstract] [Full Text] [Related]
28. Korea: the new first battleground for the high stakes poker game of pharmaceutical patent litigation. Choe JY; Yoon KA; Lee S Pharm Pat Anal; 2015; 4(6):409-13. PubMed ID: 26580988 [No Abstract] [Full Text] [Related]
29. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars. Gitter DM Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759 [No Abstract] [Full Text] [Related]
31. Staving off death: a case study of the pharmaceutical industry's strategies to protect blockbuster franchises. Gorlin DI Food Drug Law J; 2008; 63(4):823-64. PubMed ID: 19601385 [No Abstract] [Full Text] [Related]
32. Intellectual property rights and the Canadian pharmaceutical marketplace: where do we go from here? Lexchin J Int J Health Serv; 2005; 35(2):237-56. PubMed ID: 15932005 [TBL] [Abstract][Full Text] [Related]
33. EU court gets tough on patent extensions for combo products. Waters H Nat Med; 2012 Jan; 18(1):4. PubMed ID: 22227647 [No Abstract] [Full Text] [Related]
34. Biotech patents-business as usual? Lawrence S Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861 [No Abstract] [Full Text] [Related]
35. Understanding the Rewards of Successful Drug Development - Thinking Inside the Box. Khullar D; Ohn JA; Trusheim M; Bach PB N Engl J Med; 2020 Jan; 382(5):473-480. PubMed ID: 31995697 [No Abstract] [Full Text] [Related]
36. Using market-exclusivity incentives to promote pharmaceutical innovation. Kesselheim AS N Engl J Med; 2010 Nov; 363(19):1855-62. PubMed ID: 21047231 [No Abstract] [Full Text] [Related]
37. Analysis of the impact of the Uruguay Round Agreements Act on pharmaceutical patents. Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL; Beyer A; Visaria J Food Drug Law J; 2009; 64(1):171-81. PubMed ID: 19998745 [TBL] [Abstract][Full Text] [Related]
38. Intellectual property. Balancing innovation and access: patent challenges tip the scales. Higgins MJ; Graham SJ Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944 [No Abstract] [Full Text] [Related]